NASDAQ:REGNRegeneron Pharmaceuticals Stock Price, Forecast & News

Regeneron Pharmaceuticals' stock was trading at $464.70 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, REGN stock has increased by 33.6% and is now trading at $620.86. View which stocks have been most impacted by Coronavirus.

27 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 12 hold ratings, 14 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals will be holding an earnings conference call on Wednesday, August 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) released its quarterly earnings data on Tuesday, May, 5th. The biopharmaceutical company reported $6.60 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $6.13 by $0.47. The biopharmaceutical company had revenue of $1.83 billion for the quarter, compared to the consensus estimate of $1.81 billion. Regeneron Pharmaceuticals had a net margin of 28.56% and a return on equity of 24.94%. Regeneron Pharmaceuticals's quarterly revenue was up 6.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $4.45 EPS. View Regeneron Pharmaceuticals' earnings history.

Regeneron Pharmaceuticals announced that its Board of Directors has initiated a share repurchase plan on Tuesday, November 5th 2019, which allows the company to buyback $1,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to purchase up to 2.9% of its shares through open market purchases. Shares buyback plans are typically a sign that the company's management believes its shares are undervalued.

27 Wall Street analysts have issued 12 month price objectives for Regeneron Pharmaceuticals' stock. Their forecasts range from $325.00 to $750.00. On average, they expect Regeneron Pharmaceuticals' share price to reach $573.26 in the next year. This suggests that the stock has a possible downside of 7.7%. View analysts' price targets for Regeneron Pharmaceuticals.

Press coverage about REGN stock has been trending very negative this week, according to InfoTrie Sentiment. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Regeneron Pharmaceuticals earned a daily sentiment score of -3.2 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news about Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 2,470,000 shares, an increase of 24.1% from the June 15th total of 1,990,000 shares. Based on an average daily volume of 1,430,000 shares, the short-interest ratio is presently 1.7 days. Currently, 2.3% of the company's shares are sold short. View Regeneron Pharmaceuticals' Current Options Chain.

Some companies that are related to Regeneron Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include Gilead Sciences (GILD), Netflix (NFLX), NVIDIA (NVDA), Alibaba Group (BABA), Tesla (TSLA), Biogen (BIIB), Micron Technology (MU), Walt Disney (DIS), Alphabet (GOOG) and Johnson & Johnson (JNJ).

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

Regeneron Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include DNB Asset Management AS (0.07%), Envestnet Asset Management Inc. (0.06%), Hexavest Inc. (0.03%), State of Alaska Department of Revenue (0.03%), Livforsakringsbolaget Skandia Omsesidigt (0.00%) and Jacobs & Co. CA (0.00%). Company insiders that own Regeneron Pharmaceuticals stock include Andrew J Murphy, Arthur F Ryan, Bonnie L Bassler, Christopher R Fenimore, George L Sing, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Leonard S Schleifer, Michael S Brown, Neil Stahl, P Roy Vagelos, Robert E Landry and Sanofi. View institutional ownership trends for Regeneron Pharmaceuticals.

REGN stock was sold by a variety of institutional investors in the last quarter, including Jacobs & Co. CA, Carroll Financial Associates Inc., Nelson Van Denburg & Campbell Wealth Management Group LLC, HBW Advisory Services LLC, and Stonebridge Capital Management Inc.. Company insiders that have sold Regeneron Pharmaceuticals company stock in the last year include Andrew J Murphy, Arthur F Ryan, Bonnie L Bassler, Christopher R Fenimore, George L Sing, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Leonard S Schleifer, Michael S Brown, Neil Stahl, P Roy Vagelos, Robert E Landry, and Sanofi. View insider buying and selling activity for Regeneron Pharmaceuticals.

REGN stock was acquired by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, DNB Asset Management AS, Envestnet Asset Management Inc., Patton Fund Management Inc., Canandaigua National Corp, Hexavest Inc., Livforsakringsbolaget Skandia Omsesidigt, and TrimTabs Asset Management LLC. View insider buying and selling activity for Regeneron Pharmaceuticals.

Shares of REGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of REGN stock can currently be purchased for approximately $620.86.

Regeneron Pharmaceuticals has a market capitalization of $68.31 billion and generates $7.86 billion in revenue each year. The biopharmaceutical company earns $2.12 billion in net income (profit) each year or $21.47 on an earnings per share basis. Regeneron Pharmaceuticals employs 8,100 workers across the globe.

The official website for Regeneron Pharmaceuticals is www.regeneron.com.

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company can be reached via phone at 914-847-7000 or via email at [email protected]